Sorriso Announces Data Publication in Lancet Gastroenterology & Hepatology and Presentation of New Findings at UEG 2025
First-in-class Oral Dual Acting Therapy SOR102 Demonstrates Promising Safety, Pharmacokinetics, and Efficacy in Ulcerative Colitis Patients SALT LAKE, UT, UNITED STATES, November 13, 2025 /EINPresswire.com/ -- Sorriso Pharmaceuticals, a …